Krishnan Suma 4

What Happened
Suma Krishnan, reported as a 10% owner of Krystal Biotech (KRYS), sold a total of 25,000 shares in open-market transactions on June 4, 2026. The sales were executed in multiple trades at prices ranging roughly from $300.75 to $311.77. Major blocks included 12,729 shares at $307.81 ($3,918,070) and other lots (e.g., 3,803 shares at $308.89 for $1,174,708); total reported proceeds were approximately $7,702,826. These were dispositions (S = sale), not purchases.

Key Details

• Date of transactions: June 4, 2026 (Form 4 filed June 5, 2026 — timely filing).
• Shares sold: 25,000 shares; total proceeds ≈ $7,702,826.
• Price details: individual lots reported at weighted-average prices from $300.75 up to $311.77; several footnotes (F3–F12) note the sales were executed in multiple trades within specified price ranges and the listed prices are weighted averages.
• Plan: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted September 4, 2025 (plan effective December 4, 2025 through December 4, 2026 unless earlier terminated) (F2).
• Post-transaction holdings: the Form 4 does not disclose the reporting person’s remaining beneficial ownership in this filing.
• Related-party/trust notes: the filing disclaims beneficial ownership of shares directly owned by the reporting person’s spouse (reported separately) and references family/spousal trusts (F1, F13, F14).

Context

• These were planned dispositions under a 10b5‑1 plan — common for insiders to sell on a pre-set schedule; such sales are generally treated as routine rather than a direct signal of changing sentiment.
• As a 10% owner (not necessarily an executive transaction), the trades reflect an insider-level stakeholder selling shares; no options were exercised and no awards or gifts were reported in this filing.